zingo commercialization plan -...

DRAFT

ZINGO Commercialization Plan

October 2007

2

Forward Looking Statements

This presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this presentation include, without limitation, forecasts of product development, FDA filings, and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied in this presentation. Such risk factors include, among others: the results of clinical trials; whether certain market segments grow as anticipated; the competitive environment in the biotechnology industry; whether Anesiva is able to manufacture products on commercially reasonable terms; whether Anesiva can commercially release new products successfully; and the degree to which these products gain market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this presentation. Additional information concerning these and other risk factors is contained in Anesiva’s Form 10-K for the year ended December 31, 2006 and in Anesiva’s current Form 10-Q. Anesiva undertakes no obligation and do not intend to update these forward-looking statements to reflect events or circumstances occurring after this presentation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. All forward-looking statements are qualified in their entirety by this cautionary statement.

3

Agenda

Opening remarks– John McLaughlin, CEO

Manufacturing overview, readiness for launch, future plans– Jack Regan, SVP, Operations

What is it like to use Zingo and other TLAs?– Bill Zempsky, M.D., Pediatric Pain Specialist

Introduction of Commercial Team– James Huang, Marketing and Business Development Consultant to Anesiva

Unveiling the Zingo commercialization plan– Nancy Donahue, SVP, Marketing and Sales– James Carr, VP, Marketing– Michelle Chung, Director, Marketing– Diana Davidson, Sr. Director, Marketing– Nancy Donahue, SVP, Marketing and Sales

Q&A – Moderated by John McLaughlin Goal: Finish by 1:30

4

Zingo Commercial Activities

Approved for children 3 – 18 years of age for venipuncture and IV line placementsNeedle-free delivery of lidocaine particles gives rapid onset of action in 1 – 3 minutesEasily incorporated into procedureHigh unmet medical need in 18 million U.S. hospital pediatric procedures Market research indicates robust demandPediatric use guidelines already in place

5

VIDEO

6

Hospital Sales Process

1. Gain inclusion on drug formulary list

• MD requests • Pharmacy conducts evaluation

• Clinical• GPO contract

• Formulary committee reviews and decides whether to include on list

2. Demand creation• Drive use among nurses

7

Strategic Assessment

Demand CreationMarket research consistently supports strong demand by nursesVery targeted approach of 15 reps to 175 key hospitals = 75% of pediatric businessConclusion: Anesiva can do this alone

Formulary ListingFormulary listing is rate limitingConclusion: Focus on getting faster and broader formulary listing

8

Sagent and Anesiva

SAGENT

Sagent team is highly experiencedSagent is unique in this space

Anesiva + Sagent

Faster Formulary Listing + Demand Creation

Increased Sales

9

Efficient Manufacturing

Highly experienced manufacturing team Averages >15 years per personAll disciplines including automated processes and managing contract manufacturing

Efficient automated manufacturing process in place to meet capacity and cost objectives

Small-scale production available now, but wait for lower COGs $15 million invested -- state-of-the-art automationProduct available early 2Q 2008

Joint venture with Fosun will provideSignificant supplemental capacityLower cost of goodsProduction capability to meet upside demand

DRAFT

Manufacturing OverviewReadiness for Launch

Future Plans

Jack ReganSenior Vice President, Operations

11

Sound Damper

Start Button

Cover Helium Microcylind

Nozzle (Gas Path)

Breakaway Tip

Sound Damper

Lidocaine Cassette

Start Button

Cover Helium Microcylinder

Nozzle (Gas Path)

Outlet

Breakaway Tip

Safety Interlock

Zingo Manufacturing

SterileSingle useNeedle-free DisposableHelium gas delivers Lidocaine particles into the skin

12

Zingo Components

Button Cassette Assembly

Cover

Polycarbonate Membrane

Cassette Body – Male

Silencer Foam

Silencer Cover

Cassette Body –Female

Polycarbonate Membrane

Spring

Nozzle

Expansion Chamber

Filter

Housing

Retainer

BOC Microcylinder

Compliant Ball Spacer

Cassette Assembly

13

ANIMATION

14

Zingo Manufacturing

StatusZingo manufacturing approved by FDA at small scale and available for launchComparability protocols for manufacturing at large scale (powderfilling and assembly/packaging) also approved by FDALarge scale processes very similar to small scale processes but utilizes automation to increase throughput, reduce cost

EquipmentAnesiva has invested ~$15M in support of large scale part molding and manufacturing automation starting Dec. ‘05

Management TeamAnesiva CMC management average >15 years of experience in all disciplinesAnesiva CMC management is very experienced in managing CMO’s

15

Major Equipment Purchases

Major Equipment Purchase– Large scale tooling for plastic parts– Powder filler

Fills 0.5 mg Lidocaine powderAssembles drug cassette for automated assembly

– Assembly / packaging lineAutomated assembly and inspection of 14 partsAutomated labeling, pouching and cartoning into 12 unit cartons

16

VIDEO

17

Zingo Manufacturing

18

Equipment Status and Capacity

StatusFull qualification of automated line delayed 3 months due to debug issuesDelays resulted in additional run time at factory to assure

– Meets quality expectations– Confidence for commercial supply– Achieve COG’s target

CapacityCapital equipment investments provide capacity of 5M units/shift/yearMulti shift capacity 15M/year

19

Manufacturing Milestones

20

Zingo Manufacturing in China

Key ElementsManufacturing Joint Venture with Wanbang BioPharma (a subsidiary of Fosun Pharma) to assemble Zingo in China

– With U.S.-supplied parts & drug cassetteFeasibility established; facilities & equipment identifiedNo significant capital investment

Next StepsQualification activities in 1H ’08 and regulatory submissions in 2H ’08

BenefitsAssures second supply source Low cost of goods Significant upside capacity

DRAFT

Perspectives on the Need for Reducing Peripheral Venous Access Pain

William T. Zempsky, MDAssociate Professor, University of Connecticut School of Medicine

Associate Director, Pain Relief Program, Connecticut Children's Medical Center

22

Why Do We Care?

Millions of painful needle procedures in children each yearIV insertions and blood draws were the most frequently reported painful events in a study published in Pediatric Nursing

– Needle insertions can arouse more fear than major surgeries

Parents rate a needle procedure as the second most distressing event during child’s hospitalization

– Only thing worse was waiting for a child during surgery

23

Why Do I Care?

Trained in Pediatric Emergency MedicineRecognized the need for rapid acting topical anesthetic14 years looking for the ideal topicalDevoted to systematic reduction of pain in medical settings

24

What About Topical Anesthetics?

Should they be routinely used for peripheral venous access procedures

in children?

25Pediatrics. 2004;114:1348-56.

“Topical anesthetics should be placed proactively to control pain…”

“Use should be considered in any patient who has a high likelihood of undergoing a non-emergent invasive procedure

on intact skin in the ED. These include intravenous line placement or venipuncture.”

26

Papers / Guidelines Advocating Topical Anesthetics

2001, AAP/APS Position Paper1

2004, Relief of Pain and Anxiety in Emergency Medicine Systems—Clinical Report2

2005, Pediatric Procedural Pain, Review3

2006, Infusion Nursing Standards of Practice4

1. AAP/APS. Pediatrics 2001;108:793; 2. Zempsky WT et al. Pediatrics 2004;114:1348; 3. Young K. Ann Emerg Med 2005;41:160; 4. J Infusion Nursing 2006;29:1S.

27

Current Practice

National survey of Pediatric Emergency Department Fellowship Directors 1– Topical Anesthetics (TAs) use of IVs = 38% of

procedures

Single hospital retrospective study (Harbor UCLA Pediatric ED)2

– 1% treated with TAs out of 859 patients

1. Bhargava Aced Emerg Med 2007 2. Maclean et al PEC 2007

28

Why Aren’t They Used?

Creams and patches– 20-60 minute onset – Creams are messy

Facilitated drug delivery systems– Inconvenient: multiple components and

require training

29

Works quicklyEffectivePainless to administerCovers sufficient areaEasy to useSafe– Local effects– Lack of systemic absorption

Cost effective

Qualities of the Ideal Topical Anesthetic

30

Experience with Zingo in Clinical Setting

~ 500 patients treated in Zingo clinical trials at CCMC

Findings:– Nurses found Zingo easy to learn to use – Perceived as easy to incorporate into procedure – no

planning required– Effective within 1-3 minutes– Safe and well tolerated– Commonly requested for subsequent procedures

DRAFT

Introduction of Commercial Team

James HuangSales & Marketing

Consultant to Anesiva

32

Commercial Team

100+ years broad and deep blend of marketing, sales and sales management, sales training, managed markets and clinical experienceMarketing of 10+ brands and multiple blockbuster products

– Multiple launches: Avandia, Avandamet, Coreg, Provigil, Effexor (UK), Pulmicort Turbohaler (UK)

– Pre-launch preparation for surgical drug/device combination

Extensive sales experience – Over 40 brands including extensive hospital selling

experience – Pain Selling includes Duragesic, Ultram ER, Ultracet,

Topamax, Flexeril, Relafen and pain devices

33

Nancy Donahue, Sr. VP Sales & Marketing

19 years sales & marketing – 5 years of office based and hospital sales and sale

training

– Extensive launch and brand building experience: Relafen, Paxil, Mycobutin, Risperdal, Coreg, Avandia, Avandamet

– Served for 7 years as product director and senior product manager of Coreg, growing it into a billion dollar brand

– Prior joining Anesiva, Nancy led diabetes franchise marketing at GSK

– Most recently VP, Marketing at Anesiva

34

Jim Carr, VP Marketing

11 years of pharmaceutical industry experience– 2 years medical science liaison (field-based and reported

to a sales region)– 9 years of marketing and new product planning experience

Previous experience as an academic/clinical pharmacist

– 7 years working in various intensive care settings in hospitals

– Served as the Director of Pharmacy early in pharmacy career which included managing the P&T committee

35

Michelle Chung, Director, Marketing

15 years sales & marketing at major pharmaceutical companies (Wyeth, Astra, GSK, Cephalon)

– 8 years UK; 7 years US

– Extensive launch experience: Effexor (UK), PulimcortTurbohaler Once Daily Children (UK), Avandia (UK), Avandamet (US)

– Most recently, Michelle was Director on Avandia and Regional Sales Director, HIV division at GSK

– Prior to joining Anesiva, Director Provigil at Cephalon

36

Diana Davidson, Sr. Director, Marketing

30 years marketing and sales experience in pharmaceuticals and medical devices (Elan, Pharmacia, Lilly, Pfizer)

– 9 years strategic and new product planning

– Commercial development of drug/device combination products

– Physician and hospital pain marketing experience: Avinza, Naprelan, PCA devices

– Before Anesiva, Vice President of Marketing, AlgoRxPharmaceuticals; Vice President of Marketing, Elan

DRAFT

Nancy DonahueSr. Vice President, Sales and Marketing

38

Commercial Presentation Agenda

Sagent PartnershipStrategic OverviewMajor Initiatives– Market Expansion– Advocacy Development– Promotional Campaign– Clinical and

Pharmacoeconomics– Public Relations

Sales Force Rollout

N. DonahueJ. Carr

M. Chung

D. Davidson

N. Donahue

DRAFT

Sagent Partnership

Nancy DonahueSenior Vice PresidentSales and Marketing

40

Initial Launch: Pediatric Hospital Opportunity

Stand Alone

Children’sn~62

Pediatric Hospital Within Academic

n~112

Other targets (adult opportunity)

N~926

174 Hospitals represents

~75% of Ped opportunity

41

Hospital Sales Process

1. Gain inclusion on drug formulary list• MD Requests• Pharmacy conducts evaluation

• Clinical• Financial (GPO contract?)

• Formulary committee review and vote

2. Create Demand• Drive Use among nurses

42

Hospital Nurses Demand Survey

What Percentage of Your Pediatric Patients Would Receive Zingo?

63.2%Blood Draws

70.5%IV Placements

Zingo

Source: Princeton Brand Econometrics Survey of 44 Hospital-Based Nurses

43

Sagent: Ideal Zingo Partner

Focused on developing, manufacturing, sourcing and marketing hospital-based products– Goal is to supply 200 products to hospitals to 2009

Complete infrastructure for warehousing, distribution and administrative activities

44

Sagent: Warehouse & Distribution

Manages warehousing and distribution of Zingo

Manages order to cash cycle– Order entry – Invoicing – Collection– Returns and credits

45

Sagent: Unmatched Experience

Leadership team with unparalleled experience

– Executive management team has an average of more than 20 years experience and proven track record

Extremely seasoned team of sales and national accounts executives

– National Accounts individuals average over 25 years of experience and possess relationships with top level executives at all GPOs

– Field Sales organization of 15 averages over 18 years experiencecalling on hospitals

Depth of experience focused exclusively in hospital market

46

Anesiva: Hospital Sales Team

2 Directors– Highly successful hospital sales management experience – Experience building sales forces preferably at start up

organization– Well trained in leadership/mentoring

15 Sales Representatives– Highly successful hospital sales experience, including

securing formulary additions and driving uptake– Skilled in understanding hospital selling environment

Formulary process Relationship building Account management Strategic and tactical planning

47

Key selling contact for nurses

Key selling contact for physicians, P&T members

Conduct Nursing inservices

Sagent and Anesiva

Key selling contact for hospital pharmacy

Hospital contracting

Group purchase contracts

ANESIVASAGENT

Complementary and Synergistic Selling Roles

Anesiva + Sagent = Faster Formulary Listing + Demand Creation = Increased Sales

48

Benefits vs Other Partner Options

OthersMultiple products being sold - Zingo may not be top priorityInefficient – Many reps selling Zingo in a small proportion of their hospitalsProfile of reps offer no benefit over what we could build on our own

SagentZingo will be top priority during launchReps will focus energy on hospital pharmacists in key accountsTeam is unmatched in depth of experience calling on hospital pharmacists

With Sagent, we will have complementary Sales Efforts to drive faster and broader hospital uptake

DRAFT

Strategic Overview

James CarrVice President, Marketing

50

Zingo Market Opportunity

Hospital opportunity– 18M pediatric procedures– 400M adult procedures

Non-hospital segments include:– Office-based procedures (e.g. oncology)– Outpatient infusion centers– Surgical centers– Phlebotomy centers– Blood donation

Potential new indications include– Epidurals– Injections

51

Initial Launch: Pediatric Hospital Opportunity

Stand Alone

Children’sn~62


n~112


N~926



52

Approve AdoptAccelerate

M.D. advocate drives P & T Approval

Nurses influence key M.D. advocate

Pharmacy Directors

Gain advocacy among other P & T Members

Communicate approval broadly throughout hospital

Ensure Zingo is easily accessible

Orchestrate successful initial trial (inservice all shifts)

RN’s drive development of standing orders, SOPs

Accelerate routine use among RN’s

Broaden use to department targets hospital wide

Key Insights: Hospital Selling Process

ZINGO ZONE

Pharmacy Directors (gatekeepers of process)Contract (GPO and/or individual)Conduct independent evaluation (clinical and economic)

53

Key Insights: Pharmacy Directors

Insights of directors from Children’s stand alone and academic institutions with significant Pediatric services

Formulary acceptance allows ‘license to sell’– RN advocates will need to convince at least one dept head

MD to champion at P&T meeting– Pharmacy conducts independent evaluation which is

presented to P&T committee for vote

Securing cost benefit rationale will enhance formulary acceptance

Zingo profile supports price range of $12 - $16

Sources: Key Decision Makers Qual; Stand Alone Pharmacy Ad Board, December, 2005; Academic Pharmacy Ad Board March 2006; 1-1 Pharmacy Directors interviews, 2006-07

54

Conflict between time & comfort due to current drugs &

conditions

Needlesticks occur frequently & are

anxiety provoking

Needlesticks are emotional events and “tone setters”

for hospital experience

Pediatric & adult nurses are concerned “something should be

done”

…parents question whether nurses are doing all they can to alleviate needlestick

pain

As person administering, nurse

seen as “bad guy, archaic, mean”

A painful procedure can reduce patient

trust making further care challenging

Patients & nurses are comforted by

successful use of Topical Anesthetics

Sources: Ped Qual; Adult qual; Brand Personality 2006

Pain of needlesticks measured in Press

Ganey patient satisfaction survey

Nurse is Hero when needlestick goes well

Key Market Insights: Nurses

55

Zingo: Ideal Profile

Zingo Benefits: – Highly emotional

(patient comfort, positive impact on relationship with patient)

– 1-3 minute onset; easy to incorporate into procedure

1

2

3

4

5

6

7

High Likelihood to try ZingoScale 1:7

6.2 6.4

IV Start Blood Draw

Sources: Ped Qual; Adult qual; Brand Personality 2006

56

Vision

Zingo is an immutable step in the venipuncture and IV cannulation

procedure

57

Overall Launch Goal

Establish Zingo as standard of care in hospital pediatric market to set foundation for long term brand optimization

58

Key Strategies

Expand the market by making the need to treat IV pain top of mind

Develop multi-disciplinary Zingo advocacy

Create compelling promotional platform

Establish clinical and pharmacoeconomic rationale for Zingo

Drive Zingo demand by leveraging Public Relations opportunities

DRAFT

MAJOR INITIATIVESMarketing Expansion

Advocacy DevelopmentPromotional Campaign

Michelle ChungDirector, Marketing

60

Strategies #1 and #2

Expand the market by making the need to treat IV pain top of mind

Create multi-disciplinary Zingo advocacy

61

Focused Pediatric Opportunity

Stand Alone

Children’sn~62


n~112


N~926



62

Hospital Advocacy Efforts

Market Development Manager focused on targeted institutions– Developing profiles and introduce Zingo– Develop extensive profiles of >60 targeted

hospitals with relationships established with at least one influencer

Sales team deployed early 2008 and intensify efforts on key targeted institutions

63

Venipuncture Optimization through Improved Comfort and Education

Influential, action-oriented nurses from targeted hospitals with passion for reducing pediatric needlestick painMission: Transform the IV and venipuncture experienceValue of RN Voice

– Provide input and assistance in developing critical launch materials, i.e. inservice kit, speaker program slides

– Conduit for dissemination of best practices within members hospitals as well as to influence lower tier hospitals

64

Nursing Survey to Highlight Need to Treat IV Pain

Objectives:Establish that nurses view peripheral venous access pain (PVAP) in children as important and should be well managedDocument that nurses feel that current treatment options are unsatisfactory

Process:Field the survey through the following groups

– Emergency Nurses Association– Society of Pediatric Nurses– Infusion Nurses Society

Results will be abstracted and presented 1Q08Posters will appear in a formulary kitPublish manuscripts Advocates use the data as a rallying cry

65

Comfort Corner

RN VOICE Advocates Take Action To Reduce Needle-Related Pain

Leverage Best Practices from select Children’s Hospitals in an Implementation Guide

Recommended Pharmacologic Treatment GuidelineNursing Governance best practices to remove impediments

Patient Bill of RightsStanding Orders

Pilot roll out in 10 leading institutions planned 11/07

Full roll out planned for 1Q08

66

Market Development Campaign

Increase awareness of need to treat IV pain among targeted pediatric nurses

Drive hospital pediatric nurses to www.manageivpain.com through direct mail and e-mail blasts

Launch website at key conventions during 4Q07– Emergency Nurses Association (ENA)– National Association of Children’s Hospitals (NACHRI)– Association of Vascular Access (AVA)

Fill the funnel with qualified leads for launch– Enroll nurses in RN VOICE – Develop a continuous channel for Zingo launch

communications

72

Journal Supplement Highlighting Need to Treat IV Pain

“Evidence Supporting Optimal Management of Peripheral Venous Access Pain in Pediatric Patients: Why It Is Important”

Objective: Generate broad-based awareness about the importance of managing peripheral venous access procedure pain in pediatric patientsExceptional list of contributing authors Closed roundtable held July 18th, 2007 Target publication: Major pediatrics journal Q1 08

Case Profiles: Atlanta Children’s Hospital, Texas Children’s Hospital, St. Louis Children’s Hospital

Chapter 6

Neil Schechter, MD, Professor of Pediatrics, University of ConnecticutThe Ouchless Place: 10 Years Later

Chapter 5

William Zempsky, MDPharmacologic Approaches to Reduce the Pain Associated with Venous Access

Chapter 4

Lindsey Cohen, Ph.D., University of GeorgiaNon-pharmacologic Techniques to Reduce the Pain Associated with Venous Access

Chapter 3

Gary Walco, Ph.D, Professor of Pediatrics, Univ. of Medicine and Dentistry New JerseyImplications of Unmanaged Procedural Pain in Pediatric Patients

Chapter 2

William Zempsky MD, Associate Professor, Pediatrics, University of ConnecticutOverview and Introduction

Chapter 1

73

Strategy #3

Create Compelling Promotional Platform

74

Compelling Promotional Platform

Zingo enables you to positively impact the patient’s hospital experience

Needlesticks are emotional events and “tone setters” for hospital experience

Key Insight

Positioning

76

Zingo Launch Campaign

DRAFT

Clinical and PharmacoeconomicsPublic Relations

Diana DavidsonSenior Director, Marketing

78

Strategy #4

Establish Clinical and Pharmacoeconomic Rationale for Zingo

79

Publications-Manuscripts

Phase 2 Data

Accepted

Phase 3COMFORT* 003

Accepted

Phase 3COMFORT* 003/ COMFORT 004

*COMFORT Trials= COMparision of Venipuncture and Venous Cannulation Pain after Fast Onset Needlefree PowdeRLidocaine or Placebo Treatment

Journal of the American Academy of Pediatrics

Rank: 1/70 pediatric journals

Circulation: 65,000

Submission targetedto a leading

anesthesiology/pain journal

Accepted at a leading pediatric journal with

hospital focus

80

Zingo Data Presentations

Medical ConferencesNational Association of Pediatric Nurse Practitioners 2008*American College of Emergency Physicians 2007*American College of Clinical Pharmacy 2007*American Society of Regional Anesthesia and Pain Medicine 2007Association for Vascular Access 2006International Symposium on Pediatric Pain 2006Society for Academic Emergency Medicine 2006^Intravenous Nursing Society 2006Pediatric Academic Societies 2006^Society for Pediatric Anesthesiology 2006American Society of Pain Educators 2005Pediatric Academic Societies 2005American Pain Society 2005

*Accepted for publication/presentation ^Podium presentations

81

Pharmacoeconomic Initiative

Quantify the benefit of 1-3 minute onsetProcess1. Qualitative interviews

• Areas of focus: ED, Sedation Units, Radiology

2. Financial models 3. Observational studies 4. Publication of findings

82

Strategy #5

Drive Zingo demand by leveraging Public Relations opportunities

Zingo™ Approval

84

Zingo PR Launch Plan

Major national educational initiative – Appeal to parents with small children – Media targets

National television Local television Consumer outlets (print and online) Long-lead magazines (parenting, women’s, health)

Early adopter hospital PR campaign– In areas where Zingo is on formulary, raise awareness

of new treatment option to drive patient requests

85

Drive Parent Demand

Partnering with children’s chronic disease organizations to reach parents with children who receive many IV/venipuncture procedures

– Congenital Hypogammaglobinemia – Acquired Immune Deficiency – Cancer– Crohn’s – Diabetes – Hemophilia– Sickle Cell

Objective:– Raise awareness of non-pharmacologic and pharmacologic

alternatives through manageivpain.com

DRAFT

Sales Force Roll Out

Nancy DonahueSenior Vice PresidentSales and Marketing

87

Complementary and Synergistic Selling Efforts

SAGENT

Group purchase contractsHospital contractingKey selling contact for hospital pharmacy

ANESIVA

Key selling contact for nurses Key selling contact for physicians P&T membersConduct nursing inservices

88

Prepping Market for Rapid Uptake

Q407 1Q08 2Q08

Anesiva Sales Directorshired and

familiarize with key target hospitals

Sales Directors develop launch plan for top 60

hospital accounts

Anesiva Sales force hired

Anesiva & Sagent are trained and

deployed

Sagent & Anesiva build account launch

plans for top 10 hospitals per

territory

Anesiva SF develop influential MD advocates to request

formulary review & prepares for P&T meeting

Sagent SF meet Pharmacy in top 10

hospitals and ensures Zingo on P&T agendas

Zingo Available

Sagent – GPO Contracting

89

Zingo - Driving a Successful Launch

Extensive market understanding– Significant unmet need– Product failures attributed to suboptimal profiles

Ideal product profile

Focused efforts on targets to accelerate launch– Building advocacy– Making the need to treat IV pain top of mind

Synergistic sales force efforts– Anesiva -- Right profile – Sagent -- Ideal partner

Launch preparedness: Prepping the market for rapid uptake

90

Questions and Answers

John McLaughlin

Q&A

91

Zingo Summary

Zingo fulfills an important unmet needZingo widely anticipated by nurses and hospital staffVision: Zingo is an immutable step in venous access procedures

Prepping the market for rapid uptakeCreate awareness, expand demand through multiple aggressive campaignsFocused on hospital formulary adoption

Highly experienced teamNancy Donahue, James Carr, Michelle Chung and Diana Davidson: a stellar commercial team Sagent: Accelerate formulary access and increase sales

Efficient manufacturing and future offshore capacity US automated lines reduce cost of goodsChina Joint Venture» Further reduce COGs» Provide substantial additional capacity» Provides capacity for high demand scenarios» Minimal capital investment required

zingo commercialization plan -...

Documents